BioPharma Dive March 12, 2025
Kristin Jensen

The experimental medicine for polycythemia vera is currently being tested in a Phase 2 trial.

Dive Brief:

  • Ionis Pharmaceuticals is licensing out another experimental medicine, entering an agreement with Ono Pharmaceutical that offers $280 million upfront and as much as $660 million more for reaching certain development, regulatory and sales goals.
  • The drug, sapablursen, is designed to treat polycythemia vera, a rare disease that can cause life-threatening blood clots. Ionis is currently testing sapablursen in a Phase 2 trial and will continue to be responsible for that study.
  • Ono will handle development after the completion of the Phase 2 study, as well as regulatory filings and commercialization. If sapablursen reaches the market, Ionis is in line for royalties in...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Investments, Pharma, Pharma / Biotech, Trends
Related Articles:
Zealand Pharma, Roche Reach Potential $5.3 Billion Deal to Develop Petrelintide for Weight Management
STAT+: Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more
Roche builds in obesity with $5.3bn Zealand licensing deal
Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity
A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV

Share This Article